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Introduction. The main purpose of the study was to assess margin resection as a prognostic factor of vulvar cancer in 
patients with a long term follow-up. 
Materials and methods. The study included 84 vulvar cancer patients who underwent radical treatment: surgery (n = 84), 
radiotherapy (n = 16), chemoradiotherapy (n = 5). Clinicopathological factors regarding survival and recurrence were 
analyzed. The median follow-up was 74 months. 
Results. Resection margins were not related to progression-free survival (PFS) (p = 0.93) and overall survival (OS) (p = 0.84). 
On the multivariate analysis, a maximum tumor size >25 mm (p = 0.026) and inguinal lymph node involvement (p = 0.028) 
were factors increasing the risk of death. The risk of recurrence was related to tumor dimension >25 mm (p = 0.011), but 
not to inguinal node metastasis (p = 0.086). 
Discussion. Inadequate surgical margin would be salvaged by adjuvant treatment.
Conclusions. A maximum tumor dimension >25 mm and metastases in the inguinal lymph nodes are independent 
prognostic factors for the survival of patients with vulvar cancer.
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Introduction
Inguinal lymph node involvement is unquestionably a prog-
nostic factor in vulvar cancer. It is believed that resection mar-
gins are also of great importance in the management of vulvar 
cancer. Subsequently, the main goal of surgical treatment 
is to achieve a wide margin (according to NCCN: 1–2  cm, 
ESGO – 8 mm) [1, 2]. Recently, some studies question the im-
portance of a wide excision and show no correlation between 
margin width and recurrence [3, 4]. 
Follow-up is recommended in all patients for 4–5 years 
after treatment [1, 2]; conducting longer observations is 
difficult due to the advanced age of patients at diagnosis, 
limitations of healthcare, rare incidence and the dispersal 
of patients.  
The main purpose of the study was to assess margin re-
sections as a prognostic factor of vulvar cancer in long term 
follow-up. An additional aim was to identify clinicopathological 
and treatment related-factors (other than margin) influenc-
ing survival and affecting treatment failures in vulvar cancer 
patients in long term follow-up scenarios.
Material and methods
The retrospective analysis included 84 patients with vulvar 
cancer treated at Maria Sklodowska-Curie National Research 
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Institute of Oncology between 2001 and 2007. Women with 
contraindications to surgical treatment due to advanced dis-
ease and severe comorbidities were not included. The stage 
of the disease was evaluated according to the 1994 FIGO clas-
sification, which was valid at the time. For this study, staging 
was reclassified to the 2009 FIGO. All patients were diagnosed 
with vulvar squamous cell carcinoma and underwent a radi-
cal vulvectomy with inguinal lymphadenectomy. 31 patients 
required adjuvant treatment according to the following criteria: 
• resection margin ≤1 mm or positive, 
• metastasis to ≥1 inguinal lymph node. 
Ten patients did not undergo adjuvant therapy due to 
comorbidities and poor general condition (n = 3), lack of 
consent to radiotherapy (n = 2), abnormal wound healing 
(n  = 2), skipping appointments (n = 1), the patient’s death 
(n = 1), unknown reasons  (n = 1). 21 patients were treated with 
radiotherapy (RT, n = 16) and radiochemotherapy (RCT, n = 5).
Adjuvant external beam radiation therapy (EBRT) with 
linear accelerator and energy of 4–15 MeV was applied to the 
vulva (n = 6), vulva and groins (n = 5), groins (n = 5) and pelvic 
region (n = 5). A total dose of 4800–6000 cGy was adminis-
tered in 24–31 fractions. In 5 patients, concomitant cisplatin 
intravenously was administered intravenously with a dose 
of 40 mg/m2, once a week. The duration of RT and RCT was 
31–43 and 38–48 days, respectively. Adjuvant treatment started 
within 6 weeks of surgery.
Follow-up: gynecological examination, transvagi-
nal and  inguinal ultrasonography were conducted every 
3–4 months for 2 years, then every 6 months for the next 
3 years. A chest X-ray was carried out once a year. Computed to-
mography or magnetic resonance were performed in patients 
with suspicion of relapse.  After 5 years, patients continued 
follow-up once a year in our outpatient clinic or outpatient 
clinic near their place of residence. Information was obtained 
by telephone for those patients who carried out a gynecologi-
cal follow-up outside our center,  Data on death were collected 
from the National Cancer Registry. 
Recurrence: a biopsy of the suspicious lesion was per-
formed to obtain a histopathological confirmation; the date 
of the positive biopsy was considered as the moment of 
relapse. Locoregional recurrence was defined as relapse in 
the vulva and/or groins. Distant metastases were not ob-
served in the study group. Treatment of relapse disease was 
presented in table I.
Age, tumor grade, staging, maximum tumor dimension, 
depth of stromal invasion, status of inguinal lymph nodes, and the 
number of metastatic lymph nodes were considered as clinico-
pathological factors, while margin, number of resected lymph 
node and lymph node ratio were treatment-related factors. 
Methods of statistical analysis
Efficacy of treatment was measured by the probability of sur-
vival  – overall survival (OS),   progression-free survival (PFS) and 
cumulative incidence function (CIF) of local relapses. Survival 
curves were calculated using the Kaplan-Meier method. Overall 
survival was estimated  from the date of treatment initiation to 
death or the last information provided when the patient was 
alive. Progression-free survival was measured from the date 
of treatment initiation to its first failure: local relapse, distant 
metastases or death from other causes;  in the absence of 
treatment failure, PFS was estimated to the last clinical observa-
tion. To evaluate the influence  of selected factors such as age, 
grading, staging, tumor size, lymph node metastases, depth 
of invasion, margins, total number of lymph nodes removed, 
and the number of metastatic lymph nodes on OS and PFS, 
the Cox proportional hazard model was used. The influence 
of these factors on the risk of recurrence was analyzed using 
a multivariate model for competitive risks. The modeling pro-
cess used a step-by-step elimination of variables by adopting 
standard thresholds: off (>0.1) and on (<0.05). The analysis was 
carried out using the IBM SPSS Statistics 23.0 statistical package 
and the Bob Gray package [6].
Ethics approval
All procedures were conducted according to the Declaration 
of Helsinki for Medical Research involving Human Subjects. 
Institutional ethics committee approval was not required – the 
research is an ex-post analysis of clinical experience. The clinical 
decisions concerning the treatment were not influenced by 
the purpose of this paper.
Table I. Treatment of recurrence of vulvar cancer depending on location
Treatment Location of relapse
vulva (n = 23) groin (n = 12) vulva and groin (n = 2)
surgery 10 3 0
radiotherapy 3 3 0
chemotherapy 5 0 0
radiochemotherapy 2 1 0
brachyterapy 3 0 0
palliative 2 5 2
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Results
The clinicopathological characteristics of the study group 
(n = 84) was shown in table II. Patients’ average age was 66 years 
(18–94). The median tumor size was 35 mm (5–90 mm). Mi-
croinvasion (depth of stromal invasion <1 mm) was found in 1 
patient (1.2%). Median number of resected lymph nodes per 
groin was 6 (1–15). In 26 (30.95%) patients,  metastases to the 
inguinal lymph nodes were found; 13 (17.86%) patients had 
involved >1 inguinal lymph node (2 metastatic LNs in 4 patients, 
3 metastatic LNs in 3 patients, 5 metastatic LN in 3 patients, 
8 metastatic LNs in 2 patients and 9 metastatic LNs in 1 patient). 
Survival
The median overall survival (OS) and progression free sur-
vival (PFS) was 87 (95% CI: 60–114) and 60 (95% CI: 37–84) 
months, respectively. The overall 5- and 10-year survival rates 
were 62% (95% CI: 51–73%) and 39% (95%CI: 28–50%), while 
5- and 10-year PFS were 51% (95% CI: 40–62%) and 32% (95% 
CI: 22–42%), respectively.
On the multivariate analysis, the resection margin was not 
related to PFS (HR = 1.033; 95% CI: 0.51–2.11; p = 0.93) and OS 
(HR = 0.84; 95%CI: 0.41–1.73; p = 0.84).
On the multivariate analysis, factors influencing survival 
were: maximum tumor size and inguinal lymph node status 
(fig. 1, tab. III). Other clinicopathological and treatment- related 
factors did not have a significant effect on survival.
Maximum tumor size was the only factor influencing PFS 
on multivariate analysis; nor  inguinal lymph node involvement 
or other analyzed factors were not relevant to PFS (fig. 2, tab. III). 
Failure patterns
The majority of relapses occurred within 2 years from the 
end of treatment and were localized on the vulva and groins. 
Cumulative incidence function (CIF) curves according to the 
site of relapse as competing risk had similar patterns for 2 years 
(fig. 3). At 15 years, CIF by site of relapse and non-cancer death 
as competing risk were: vulva 28% (95% CI: 18–38%), groin 
17% (95% CI: 8.7–25%) and non-cancer death 27% (95% CI: 
18–37%). Late recurrences (>5 years after the end of the treat-
ment) affected the vulva.
Occurrence of locoregional relapse (vulva and/or groins) 
was significantly dependent on the maximum tumor size 
(p  =  0.019). In the final model, the HR was 2.37 (95% CI: 
1.15–4.89) for tumors >25 mm vs. ≤25 mm. The CIF curves are 
presented in figure 4. Other clinicopathological and treatment-
related factors (including resection margin) did not have an 
influence on the risk of relapse.
Survival after recurrence
Groin recurrence influenced OS significantly (p < 0.007). The 
median survival after relapse in patients with groin recurrence 
vs vulva recurrence was 6.1 (95% CI: 2.7–9.5) vs. 16 (95% CI: 
8.7–23.5) months, respectively.
Discussion
The principles of surgical treatment of vulvar cancer are ingui-
nal lymph node assessment and wide margin excision. It was 
showed that margins ≥5 mm or ≥8 mm were significantly as-
sociated with risk of recurrence and survival [5–7]. In our study, 
the margin did not influence survival and recurrence. However, 
some patients with a close resection margin received adjuvant 
radiotherapy, which could affect the results. Similar results to 
ours were obtained in other studies [8–10]. Arvas et al.  showed 
that a margin ≤2 mm may increase the risk of recurrence, but 
was not an independent predictive factor for PFS and OS 
[11]. Woelber et al. showed a similar rate of local recurrence 
in patients with a margin <8 mm vs. ≥8 mm (12.6% vs. 10.2% 
respectively) [12]. German recommendations accept a margin 
of 3 mm as sufficient [13]. Several authors claim that a positive 
margin is the only risk factor for recurrence; a complete resec-
tion with no lower limit (besides positive margin) should be 
recommended [14–16]. 
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ing the risk of recurrence. The results of other authors also 
indicate that the tumor size and the involvement of regional 
lymph nodes influence survival. Minar et al. showed that a tu-
mor dimension >40 mm and  metastases in inguinal lymph 
nodes are significantly associated with a risk of recurrence [17]. 
Long-term observation showed that a tumor size >25 mm 
and metastases to regional lymph nodes increased the risk 
of death in patients with vulvar cancer. Inguinal lymph node 
involvement has been directly related to shorter survival, while 
maximum tumor size negatively influenced survival by increas-
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Table III. Multivariate analysis of clinicopathological factors affecting overall survival
Endpoint Factor HR 95% CI p
overall survival maximum tumor dimension ≤25 mm 1
>25 mm 2.038 1.091–3.808 0.026
groin lymph nodes metastasis no 1
yes 1.903 1.074–3.372 0.028
progression free survival maximum tumor dimension ≤25 mm 1
>25 mm 2.208 1.203–4.055 0.011
groin lymph node metastasis no 1
yes 1.625 0.933–2.830 0.086
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Hay et al. found that tumors >4 cm increased disease-specific 
mortality 4-fold , but were not related to relapse [18]. Imoto et 
al., on multivariate analysis, showed that inguinal lymph node 
involvement influenced PFS, but not OS [5]. 
The extracapsular spread of lymph nodes was found to be 
an independent prognostic factor for recurrence (HR 13.54; 
95% CI: 2.87–64.07; p = 0.01) and overall survival (HR 10.63; 
95% CI: 1.65–68.57; p = 0.01) [19]. An increasing number of 
metastatic lymph nodes was associated with a risk of recur-
rence and death [20, 21]. In our study, there was no relationship 
between the number of metastatic lymph nodes and survival, 
probably due to the insufficient number of patients.
Our results, showing that tumor grade did not influence 
recurrence risk and survival, were consistent with other studies 
[8, 19, 21–24]. Although Nicoletto et al. on univariate analysis 
showed that grading was associated with PFS and OS (5-year 
survival 52% for grade 1; 24% for grade 2 vs. 0% for grade 3, 
p = 0.0021); these findings were not confirmed on multivariate 
analysis [25]. Mahner et al. and Polterauer et al. demonstrated 
that tumor grade is predictive for PFS, but not for OS [21, 26]. 
Multivariable analysis by Sznurkowski et al. revealed that grad-
ing was an independent prognostic factor [27].  
The depth of stromal infiltration is crucial to confirm mi-
croinvasion (≤1 mm; FIGO IA). In these cases, verification of 
inguinal lymph nodes may be omitted due to the minimal risk 
of metastases. The depth of infiltration in invasive disease does 
not influence therapeutic decisions and its impact on survival is 
doubtful. We did not find a relationship between the depth of 
invasion and the risk of relapse in the primary site, PFS and OS 
length. Similar results were obtained by other authors [19, 21, 
23, 27, 28]. Contrary to this, Nicoletto et al. demonstrated that 
stromal invasion >9 mm was an important prognostic factor 
for PFS (HR = 3.1; 95% CI: 1.3–7.7) (25). While in the VULCAN 
study, stromal invasion >5 mm appeared to significantly impact 
overall survival [29].
The results of our study indicate the need for long-term 
observation of vulvar cancer patients. Relapses of the dis-
ease can occur years after the end of the treatment (fig. 4). In 
our study group, all cases of late recurrence were located in 
the vulva. Many patients after the standard 5-year follow-up 
continue healthcare beside oncology unit/outpatient clinic. 
General practitioners or obstetricians/gynecologists as well 
as patients should be informed about the possibility of late 
relapse and its most frequent location. 
The site of locoregional relapse influenced survival. Groin 
recurrence was associated with a much poorer prognosis than 
vulvar relapse. Moreover, almost all cases of inguinal relapse 
occurred within 2 years after the end of treatment (fig. 4). 
Similar observations were presented by Cormio et al., who 
showed that the median survival after groin recurrence was 
9 months and the median time from primary surgery to groin 
relapse was 7 months [30].
Conclusions 
The conclusions of the study are: 
• a tumor size  >25 mm and inguinal lymph node involve-
ment are independent prognostic factors for survival in 
vulvar cancer patients, 
• groin recurrence is associated with an unfavorable prognosis,
• vulvar cancer relapses may occur many years after treat-
ment; at the time it is located on the vulva,
• an inadequate surgical margin would be salvaged by RT 
or RCT.
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